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patients (pts). Although transport by the Emergency Medical Services (EMS)
is strongly recommended, other ways of transportation continue to be used. 
The aim of this analysis was to examine the evolution over time of the dif-
ferent ways of transport among the MIRAMI registry pts.
Methods and Results. From January 1995 to April 2011, 1353 pts were
enrolled in the the MIRAMI (MonastIR Acute Myocardial Infarction) registry.
Three ways of pre-hospital transport including self-transport, non medicalized
ambulance and EMS were used in our population. The use of theses ways over
time was analyzed on the 17 year – study period and shown in the figure
below: 
A significant (p=0.002) increase in the use of EMS was observed whereas
a proportion of approximately one third of the population continues to use a
self transport over the 17 year-study period. 
Conclusions. In our MIRAMI registry STEMI Patients transported by
EMS are significantly increasing during the last 17 years. However, approxi-
mately one third of these patients continue to use a self transport to get to the
hospital.
063
A single pre-hospital enoxaparine protocole for all STEMI admitted
to ICU: one year experience and one year follow-up in Haut Lévêque
cardiological hospital. 
Benjamin Seguy [Orateur] , David Naibo, Frederic Casassus, Edouard
Gerbaud, Lionnel Leroux, Catherine Jais, Pierre Coste
Hôpital Cardiologique du Haut Lévêque, Unité de Soins Intensifs, Pessac,
France
Goal: 30 day and 1 year follow up of a STEMI population homogeneiously
treated with prehospital enoxaparin who underwent angioplasty.
Population and methods: 203 patients were included from june 2007 to
june 2008. 61 for the fibrinolysis group and 142 for the PPCI group. All
patients benefited of a clopidogrel loading dose (300 mg or 600 mg) and
aspirine (250 mg). Tenecteplase was the only fibrinolytic used. Enoxaparine
was given with a fixed intraveinous bolus (30 mg)and a subcutaneous dose 
(0,1 mk/kg). 30 day and 1 year data were obtained using data analysis or
phone call contact with patient, GP or cardiologist.
Results: 1 month mortality is 4,4% and 1 year mortality 5,9%. IIb/IIIa GPI
have 81%
prescription rate. There is no significant difference in term of events
between the PPCI group and the fibrinolysis group. Shock, severe bleedings,
longer ischemia times were predictive for events in the follow up.
Conclusion: On a « real life » STEMI population, enoxaparin use shows
very similar results to the one oberved in studies and registry with enoxaparin
use in term of ischemic and hemorragic events. Thus , our enoxaparin protocol
provide adequate anticoagulation simple to provide in pre hospitalary settings
indifferently of the reperfusion treatment realised.
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Cytochrome P450 2C19 polymorphism in patients treated with clopi-
dogrel after percutaneous coronary intervention
Leila Abid [Orateur] (1), L Laroussi (1), Nouha Abdelmoula (2), Rania
Abdelhédi (3), Najla Kharrat (3), Amine Bahloul (1), Mourad Hentati (1),
Samir Kammoun (1)
(1) Hôpital Hédi Chaker, Cardiologie, Sfax, Tunisie – (2) Laboratoire
d’Histologie , FMS, Sfax, Tunisie – (3) CBS Center , Sfax, Tunisie
Background: Clopidogrel and low-dose aspirin have become the main-
stay oral antiplatelet regimen to prevent recurrent ischaemic events after
acute coronary syndromes or stent placement. The frequent genetic func-
tional variant 681 G>A (*2) of cytochrome P450 2C19 (CYP2C19) is an
important contributor to the wide variability between individuals of the anti-
platelet effect of clopidogrel. We assessed whether the CYP2C19*2 poly-
morphism affected long-term prognosis of patients who were chronically
treated with clopidogrel.
Methods: Between May 2009, and september 2010, 100 patients who
underwent a percutaneous coronary intervention (PCI) and were exposed to
clopidogrel treatment for at least one month, were enrolled in our study. They
underwent CYP2C19*2 determination. The primary endpoint was a composite
of death, myocardial infarction, and urgent coronary revascularisation occur-
ring during exposure to clopidogrel.
Results: Median clopidogrel exposure time was 6,67+/–6,38 months.
Baseline characteristics were balanced between carriers (heterozygous *1/*2,
n=23) and non-carriers (n=77) of CYP2C19*2 variant. The primary endpoint
occurred more frequently in carriers than in non-carriers (18,2% versus 5,3%
p=0·075). No significant differences were noted between the two groups
regarding the occurrence of stent thrombosis.
Conclusion. The CYP2C19*2 genetic variant is a major determinant of
prognosis in patients who are receiving clopidogrel treatment after PCI.
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Mediterranean diet decrease homocysteine levels and increase thiolac-
tonase activities in elderly patients at high risk of cardiovascular
disease
Sonia Hammami [Orateur] , Nadia Koubaa, Amel Nkbi, Soumira Mehri,
Mohamed Hammami
Faculté de Médecine Monastir, Nutrition Humaine et Désordres Métabo-
liques, Monastir, Tunisie
Background: Food items might have a synergistic and antagonistic
effect on health. The Mediterranean diet has long been associated with
lower incidence of cardiovascular disease. Elevated blood homocysteine is
a risk factor for cardiovascular disease. Thiolactonase; the antioxidant
enzymatic component of HDL plays a crucial role in metabolizing homo-
cysteine thiolactone and reducing homocysteine endothelial damages.
Objective: A total of 53 elderly coronary artery disease patient were
recruited and divided into diabetic patient (n= 27; age= 68.3years) and non
diabetics (n=26; age= 68.7 years). We evaluated plasma homocysteine levels
(tHcy); thiolactonase activity (HTase) and studied the effects of adherence to
a Mediterranean diet on them.
Methods: tHcy was determined by a validated highly sensitive and accu-
rate capillary gas chromatography mass spectrometry method (GC-MS);
HTLase was estimated by a commercially available kit assay. Dietary intakes
were evaluated by a validated food frequency questionnaire 
Results: Significantly higher tHcy levels were found in diabetic patients as
compared to non diabetic (18.5 μmol/L (15-24) vs. 15.8 (14-17); p=0.05) asso-
ciated to lower HTase activities (266.8U/L (162-365) vs. 327.4 (240 –406);
p=0.05). Moreover, in the diabetic tHcy levels were negatively associated with
thiolactonase activities (r=–0.63; p- 0.00). In this group, Mediterranean diet
Results
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reduced diastolic blood pressure (r=–0.55; p=0.01). In the non diabetic group,
tHcy levels were negatively correlated with HTase activities (r=0.75; p=0.00)
and diet score (r=–0.70; p=0.01) while HTase activities were positively corre-
lated with diet score (r= 0.75; p= 0.00). 
Conclusion: Elevated homocysteine in diabetic patients may partly be
explained by the diminished HTase and could be considered as an additional
risk factor for cardiovascular events. Adherence to Mediterranean diet could
be the first efficient step to prevent these complications.
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Left main coronary stenting in a non surgical octogenarian popula-
tion: a possible approach
Ziad Dahdouh [Orateur] , Vincent Roule, Mathieu Bignon, Guillaume
Malcor, Rémi Sabatier, Thérèse Lognoné, Gilles Grollier
CHU de Caen, Caen, France
Aims. Coronary artery bypass grafting is conventionally considered the
standard treatment for significant left main coronary artery (LMCA) disease.
The management of severe coronary artery disease in the octogenarians is still
highly debated. The aim of this study was to appreciate safety and effective-
ness of percutaneaous coronary intervention (PCI) in octogenarians who were
denied by the heart team for surgical revascularization.
Methods and Results. The study included 70 consecutive patients
80 years of age who had undergone PCI for the treatment of LMCA and
who were primary denied by our center’s heart team for surgical revascular-
ization. In our study mean age was 83.4 ± 2.6 years [range 80-89]. Mean
Euroscore was 21.1 ± 16.7 and mean Syntax score was 28.6 ± 8.7. Ten (14%)
were treated with LMCA PCI in the context of ST-segment Elevation Myo-
cardial Infarction (STEMI). Overall in-hospital mortality was 11%. There
were two cases of fatal stent thrombosis at 2 and 7 days respectively after
DES implantation. Mean follow-up time was 27.2 ± 24.9 months [range 4-80
months]. Overall mortality at the end of follow-up was 28%. Cardiac death
was found in 18 patients and 2 patients died from terminal renal insufficiency.
2 other patients (3%) presented with a new STEMI, 7 (10%) with a new non-
STEMI, 13 (19%) with heart failure and 2 (3%) had minor hemorrhage. There
was a percutaneous target vessel revascularization in 7 (10%) patients. During
follow-up, the total major adverse cerebral and cardiovascular event
(MACCE) was 48.5%. Distal LMCA disease and male sex were independent
factors predicting mortality (p<0.05). 
Conclusions. Stent implantation was technically feasible and relatively
safely applied for the treatment of LMCA disease in octogenarian who were
refused for surgery and who represented a high risk population for PCI and
coronary events. Despite a high rate of MACCE, the clinical long term out-
come seems good for this specific population with heavy basal status.
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CYP2C19 but not PON1 genetic variants influence clopidogrel pharma-
cokinetics, pharmacodynamics and clinical efficacy in post-myocardial
infarction patients
Jean-Philippe Collet, Jean-Sébastien Hulot [Orateur] , Guillaume Cayla,
Johanne Silvain, Anne Bellemain, Farzin Beygui, Olivier Barthelemy, Fré-
dérick Allanic, Gilles Montalescot
AP-HP, CHU Pitié-Salpêtrière, Cardiologie, Paris, France
Background: Reduced concentrations of clopidogrel active metabolite
have been associated with diminished platelet inhibition and higher rates of
adverse cardiovascular events. Paraoxonase-1 (PON1) has recently been pro-
posed as a key enzyme for clopidogrel metabolic activation. We tested the
effects of PON1 polymorphisms on clopidogrel pharmacokinetics (PK) and
pharmacodynamics (PD), and the occurrence of cardiovascular outcomes in
young post-MI patients treated with clopidogrel.
Methods and Results: We genotyped PON1 (Q192R and L55M) and
CYP2C19 variants in 106 patients enrolled in the PK/PD CLOVIS-2 trial.
Patients were randomly exposed to 300mg or 900mg clopidogrel loading dose
in a cross-over study design. Clopidogrel active metabolite isomer H4 (clopi-
H4) and platelet function testing were measured serially post-loading dose.
There was no significant association between PON1 Q192R or L55M and
clopi-H4 formation or antiplatelet response to clopidogrel following either
loading dose. Using multivariable linear regression analyses, the CYP2C19*2
allele was the only predictor of clopi-H4 generation and platelet response irre-
spective of the platelet function assay. CYP2C19 loss-of-function but not
PON1 variants were significantly associated with increased risk of major car-
diovascular events (death, myocardial infarction and urgent coronary revascu-
larization) occurring during long-term clopidogrel exposure in 371 young
post-MI patients (<45 years) enrolled in the AFIJI cohort: CYP2C19 loss-of-
function allele carrier vs non carrier, HR 2.26 95%CI [1.15-4.41], p=0.02;
PON1 QQ192 vs QR/RR192, HR 1.03 95%CI [0.50-2.11], p=0.93; PON1
MM55 vs ML/LL55, HR 1.52 95%CI [0.75-3.08], p=0.24. 
Conclusion: Our study does not confirm that PON1 Q192R or L55M can
influence clopidogrel PK or PD in post-MI patients.
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Magnetocardiographic indices in assessment of patients with myocar-
ditis and acute STEMI
Alexander Parkhomenko [Orateur] (1), Volodymyr Sosnytskyy (2), Olga
Gurjeva (1), Taisya Sosnitskaya (2)
(1) NSC Ukrainian Institute of Cardiology, Emergency Cardiology, Kyiv,
Ukraine – (2) Kyiv Medical Group, Kyiv, Ukraine
Aims: To assess ability of different magnitocardiogtaphic (MCG) indices
to discriminate between ischemic changes of electrophysiologic properties of
myocardium early after STE AMI and non-ischemic changes.
Methods: 32 pts with STE AMI (21 pts with ischemia on stress test – 1st
group and 11 pts without ischemia – 2nd group examined on 7-10th day after
STE AMI) , 32 pts with myocarditis (3rd group) and 34 healthy (4th group)
were evaluated . All patients had neither conduction abnormalities, ischemic
changes on resting ECG, nor LV hypertrophy, systolic dysfunction on
EchoCG. Healthy and AMI pts had exercise test on the same day with MCG.
Averaged deviations of largest vectors of current density distributions (CDD)
on ST slope starting at 60 ms from J to Tapex (first half of this ST portion –
D1, second half – D2), second portion of Ta-Te (D4) and differences in direc-
tions of vectors of CDD on R and Tapex (delta RTa), ratios between global
CDD on peak R to that on Tapex (GCDD-RTa) were assessed.
Results: In 1st, 2nd, 3rd and 4th groups median D1 were 9.0, 5.0 ,3.0, and
2.25 grads respectively, p<0.05; median D2 were 11.9, 5.3 , 3.5, and 1.60
grads, p<0.01; D4 were 12.3, 6.3 , 7.3, and 5.0 grads, p<0.05; median delta
RTa were 47.0, 32.5, 22.5 and 12.5 grads respectively, p<0,01. Best sensitivity
(91%) and specificity (71% and 76%) in discerning patients with and without
ischemia after MI were D2> 8.1 and delta RT >69.5 grads. 
Of parameters consistent with myocarditis was ratio GCDD-RTa (In 1st,
2nd, 3rd and 4th groups median GCDD-RTa 3.24, 4.01, 7.13 and 5.0 respec-
tively, p<0,01 between 3rd group and other study groups) which did not differ
significantly in STEMI patients. 
Conclusion: MCG is informative for assessment of patients with and
without coronary artery disease. MCG is capable of detection changes in elec-
trophysiologic properties in myocardium susceptible to ischemia and may be
used to select patients with STE MI who need revascularization. 
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Evaluating in a “real-world” the performance of CRUSADE and
MEHRAN bleeding risk scores to predict major bleeding complica-
tions among Tunisian patients with ACS
Faouzi Addad [Orateur] (1), Majdi Amami (2), Rym Chrigui (2), Nadia Ham-
mami (2), Sami Gargouri (2), Samira Chine (2), Sonia Marrakchi (2), Zied Bel
Hadj (2), Afef Ben Halima (2), Ikram Kammoun (2), Salem Kachboura (2)
(1) EPS Fattouma Bourguiba, service de cardiologie, Monastir, Tunisie –
(2) CHU A. Mami, Cardiologie, Ariana, Tunisie
Background: Bleeding is a major complication in patients treated for acute
coronary syndromes (ACS) with antithrombotic and invasive therapies. Con-
sequently, the benefit of such therapies should be balanced against the poten-
tial risk of hemorrhagic complications. CRUSADE and more recently
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